60. 再生不良性貧血 Disease details / Clinical trials / Drug dev / DR info

Abatacept
   Emory University
      2014   Phase 1   NCT01917708   United States
   Peking University People's Hospital
      2024   Phase 1/Phase 2   NCT06279494   -
Aciclovir
   José Miguel Cisneros Herreros
      2012   Phase 3   EUCTR2011-005152-34-ES   Spain
Alefacept
   Emory University
      2010   -   NCT01319851   United States
   The Cleveland Clinic
      2011   Phase 1   NCT01267643   United States
Alemtuzumab
   Beth Israel Deaconess Medical Center
      2002   Phase 2   NCT00533923   United States
   Boston Children's Hospital
      2012   Phase 2   NCT01659606   Norway;Sweden;United States
   Federico II University
      2006   Phase 2   NCT00895739   Italy
   GCP-ISS HE0403 group
      2004   Phase 1,2   JPRN-C000000356   Japan
   M.D. Anderson Cancer Center
      2010   Phase 2   NCT01191749   United States
   Masonic Cancer Center, University of Minnesota
      2018   Phase 2   NCT03579875   United States
      2015   -   NCT02162420   United States
   National Heart, Lung, and Blood Institute (NHLBI)
      2005   Phase 2   NCT00260689   United States
      2005   Phase 2   NCT00195624   United States
   UNIVERSITA` DEGLI STUDI DI NAPOLI FEDERICO II
      2007   -   EUCTR2008-001151-22-IT   Italy
Alemtuzumab and rituximab
   Hospital Universitario Dr. Jose E. Gonzalez
      2011   -   NCT01408342   Mexico
Alkeran
   King's College Hospital NHS Foundation Trust
      2008   Phase 2   EUCTR2007-001657-26-GB   United Kingdom
Allogeneic bone marrow transplantation
   Fred Hutchinson Cancer Research Center
      2006   Phase 2   NCT00358657   United States
      2006   Phase 2   NCT00343785   Canada;United States
   H. Lee Moffitt Cancer Center and Research Institute
      1996   Phase 2   NCT00005852   -
   Northwestern Memorial Hospital
      2001   -   NCT00017654   United States
   Roswell Park Cancer Institute
      2002   Phase 2   NCT00053989   United States
   University of California, San Francisco
      2005   -   NCT00295997   United States
Allogeneic donor derived B-lymphocytes
   University of Erlangen-Nürnberg Medical School
      2013   Phase 1/Phase 2   NCT02007811   Germany
Allogeneic hematopoietic stem cell transplantation
   Memorial Sloan Kettering Cancer Center
      2018   Phase 1   NCT03531736   United States
   Roswell Park Cancer Institute
      2017   Phase 1/Phase 2   NCT03192397   United States
      2012   Phase 2   NCT01529827   United States
      2009   -   NCT00856388   United States
   Sidney Kimmel Cancer Center at Thomas Jefferson University
      2015   Phase 2   NCT02566304   United States
      2012   Phase 2   NCT01760655   United States
      2011   Phase 2   NCT01384513   United States
   Zhejiang University
      2024   Early Phase 1   NCT06633328   China
Allogeneic hematopoietic stem cell transplantation stem cell source only bone marrow
   Assistance Publique - Hôpitaux de Paris
      2024   Phase 2   NCT06646497   France
Allogeneic stem cell transplant
   St. Jude Children's Research Hospital
      2002   -   NCT00186797   United States
Allogenic stem cell transplantation
   Assiut University
      2019   Phase 2/Phase 3   NCT03295058   -
Allopurinol
   The Seventh Affiliated Hospital, Sun Yat-sen University
      2023   Phase 4   ChiCTR2200056659   China
Alpha beta depletion
   Mitchell Cairo
      2021   Phase 2   NCT04099966   United States
AMG531
   Kyowa Kirin Co., Ltd
      2019   Phase 2-3   JPRN-jRCT2080224878   Asia except Japan;Japan
      2019   Phase 2-3   JPRN-jRCT2080224673   Asia except Japan;Japan
   Kyowa Kirin Co., Ltd.
      2016   Phase 2-3   JPRN-jRCT2080223188   Asia except Japan;Japan
   Kyowa Kirin Korea Co., Ltd.
      2014   Phase 2   NCT02094417   Korea, Republic of
Amikacin
   José Miguel Cisneros Herreros
      2012   Phase 3   EUCTR2011-005152-34-ES   Spain
Amphotericine B, liposome
   José Miguel Cisneros Herreros
      2012   Phase 3   EUCTR2011-005152-34-ES   Spain
Androgens
   Shengyun Lin
      2018   -   NCT03218657   China
   The First Affiliated Hospital of Zhejiang Chinese Medical University
      2025   -   ChiCTR2500100409   China
Animal tissue extracts
   Amgen, Inc.
      2023   Phase 2   EUCTR2022-001257-22-FR   Brazil;France;United Kingdom;United States
ANTI-human immunoglobulin, equine
   Pfizer Inc.
      -   Phase 3   EUCTR2021-002155-11-Outside-EU/EEA   Japan
ANTI-human T-lymphocyte immunoglobulin from horse
   Pfizer Inc.
      -   Phase 3   EUCTR2021-002155-11-Outside-EU/EEA   Japan
ANTI-human thymocyte immunoglobulin, equine
   Pfizer
      2024   -   NCT06039020   Japan
ANTI-human thymocyte immunoglobulin, rabbit
   Peking Union Medical College Hospital
      2023   Phase 4   NCT05996393   China
ANTI-thymocyte globulin
   Anhui Provincial Hospital
      2023   -   NCT06039436   China
   Asan Medical Center
      2012   Phase 2   NCT01759732   Korea, Republic of
      2009   Phase 1/Phase 2   NCT01105273   Korea, Republic of
   Case Comprehensive Cancer Center
      2002   Phase 1   NCT00054236   United States
      2000   Phase 2   NCT00006379   United States
      1998   Phase 2   NCT00003336   United States
   City of Hope Medical Center
      2024   Phase 1   NCT05757310   United States
   EBMT (European Group for Blood and Marrow Transplantation)
      2009   -   EUCTR2007-000902-55-DE   France;Germany;United Kingdom
   EBMT (European group for Blood and Marrow Transplantation)
      2008   Phase 2   EUCTR2007-000902-55-FR   France;Germany;United Kingdom
      2007   Phase 2   EUCTR2007-000902-55-GB   France;Germany;United Kingdom
   Fred Hutchinson Cancer Research Center
      2006   Phase 1   NCT00354419   United States
      2006   Phase 2   NCT00343785   Canada;United States
   H. Lee Moffitt Cancer Center and Research Institute
      1996   Phase 2   NCT00005852   -
   Institute of Hematology & Blood Disease Hospital Chinese Academy of Medical Sciences
      2021   Phase 0   ChiCTR2100045322   China
   M.D. Anderson Cancer Center
      2019   Phase 1/Phase 2   NCT03622788   United States
      2012   Phase 2   NCT01624805   United States
   Masonic Cancer Center, University of Minnesota
      2015   -   NCT02162420   United States
   Memorial Sloan Kettering Cancer Center
      1995   Phase 2   NCT00002718   United States
   National Center for Research Resources (NCRR)
      1995   Phase 2   NCT00004323   United States
   National Heart, Lung, and Blood Institute (NHLBI)
      2005   Phase 2   NCT00260689   United States
   Northwestern Memorial Hospital
      2001   -   NCT00017654   United States
   Novartis Pharmaceuticals
      2020   Phase 2   NCT04328727   China;Japan;Korea, Republic of;Taiwan
   Roswell Park Cancer Institute
      2009   -   NCT00856388   United States
      2002   Phase 2   NCT00053989   United States
      1998   Phase 3   NCT00004474   United States
      1998   Phase 2/Phase 3   NCT00003816   United States
   St. Jude Children's Research Hospital
      2021   Phase 2   NCT04558736   United States
   The Cleveland Clinic
      2005   Phase 2   NCT01231841   United States
   University of California, San Francisco
      2005   -   NCT00295997   United States
Antilymphocyte serum
   National Heart, Lung, and Blood Institute (NHLBI)
      1982   Phase 3   NCT00000597   -
Antithymocyte globulin
   Amgen
      2023   Phase 2   NCT05323617   -
   M.D. Anderson Cancer Center
      2006   Phase 1/Phase 2   NCT00474747   United States
      2000   -   NCT00427336   United States
   Masonic Cancer Center, University of Minnesota
      2007   Phase 2/Phase 3   NCT00455312   United States
   Medical College of Wisconsin
      2017   Phase 2   NCT02918292   United States
   Memorial Sloan Kettering Cancer Center
      2018   Phase 1   NCT03531736   United States
   National Heart, Lung, and Blood Institute (NHLBI)
      1997   Phase 2   NCT00001626   United States
   Shimonaga Contact Masahiro
      2023   Phase 2   JPRN-jRCT2031230178   -
Antiviral therapy
   City of Hope Medical Center
      2010   -   NCT01199562   United States
AP1903
   Bellicum Pharmaceuticals, Inc.
      2017   Phase 1;Phase 2   EUCTR2016-003226-16-IT   Italy
      2017   Phase 2   EUCTR2014-000584-41-ES   Italy;Spain;United Kingdom
      2014   Phase 1;Phase 2   EUCTR2014-000584-41-IT   Italy;Spain;United Kingdom
      -   Phase 2   EUCTR2014-000584-41-GB   Italy;Spain;United Kingdom
Apheresis
   National Heart, Lung, and Blood Institute (NHLBI)
      2001   Phase 1   NCT00011830   United States
Assessment OF therapy complications
   Vanderbilt University
      2009   -   NCT00993694   United States
   Vanderbilt-Ingram Cancer Center
      2009   -   NCT00960050   United States
ATG
   Boston Children's Hospital
      2023   Phase 3   NCT05600426   Canada;United States
   Chinese Academy of Medical Sciences
      2010   Phase 4   NCT01997372   China
   Department of Hematology, Second Medical Center, Chinese PLA General Hospital
      2020   Phase 2   ChiCTR2000028833   China
   Federal Research Institute of Pediatric Hematology, Oncology and Immunology
      2016   Phase 3   NCT03413306   Russian Federation
   Institute of Hematology, People's Hospital, Peking University
      2019   -   ChiCTR1800019669   China
   Kanto Study Group for Cell Therapy
      2011   Phase 2   JPRN-UMIN000006071   Japan
   Medical College of Wisconsin
      2017   Phase 2   NCT02918292   United States
   Memorial Sloan Kettering Cancer Center
      2009   Phase 2   NCT00987480   United States
   Michael Pulsipher
      2016   -   NCT02845596   United States
   National Heart, Lung, and Blood Institute (NHLBI)
      2009   Phase 2   NCT00944749   United States
      2000   Phase 2   NCT00001964   United States
   National Institute of Blood and Marrow Transplant (NIBMT), Pakistan
      2018   Phase 2   NCT03955601   Pakistan
   Navy General Hospital, Beijing
      2015   Phase 1/Phase 2   NCT02407470   China
   Peking University People's Hospital
      2024   Phase 1/Phase 2   NCT06279494   -
   The First Affiliated Hospital with Nanjing Medical University
      2024   Phase 3   ChiCTR2400087735   China
   The Second Affiliated Hospital of Xi'an Jiaotong University (Xibei Hospital)
      2021   Phase 0   ChiCTR2100047288   China
   Tianjin Medical University General Hospital
      2023   -   ChiCTR2300072983   China
   University of Illinois at Chicago
      2000   -   NCT01499147   United States
   Zhejiang Provincial Hospital of Traditional Chinese Medicine
      2021   -   ChiCTR2100050948   China
ATG+cyclosporine
   National Heart, Lung, and Blood Institute (NHLBI)
      2003   Phase 2   NCT00061360   United States
ATG+rapamune+cyclosporine
   National Heart, Lung, and Blood Institute (NHLBI)
      2003   Phase 2   NCT00061360   United States
ATG-fresenius
   National Institute of Blood Disease Center, Pakistan
      2013   -   NCT02028416   Pakistan
Atgam
   National Heart, Lung, and Blood Institute (NHLBI)
      2009   Phase 2   NCT00944749   United States
   Pfizer Inc.
      -   Phase 3   EUCTR2021-002155-11-Outside-EU/EEA   Japan
Atgam 50 MG/ML, solution à diluer pour perfusion
   Amgen, Inc.
      2023   Phase 2   EUCTR2022-001257-22-FR   Brazil;France;United Kingdom;United States
Atgam plus CSA with or without eltrombopag
   European Society for Blood and Marrow Transplantation
      2021   -   NCT05049668   France
Avatrombopag
   Capital Medical University, National Center for Children’s Health
      2022   Phase 4   ChiCTR2200057674   china
   Institute of Hematology & Blood Diseases Hospital
      2022   Phase 2   NCT05720234   China
   Peking Union Medical College Hospital
      2023   Phase 2   NCT06004752   China
      2023   Phase 4   NCT05996393   China
   Tianjin Medical University, General Hospitial
      2021   Phase 4   ChiCTR2100050045   China
Avatrombopag +rhtpo
   Institute of Hematology & Blood Diseases Hospital, China
      2024   Phase 2   NCT06254287   -
Avatrombopag 20 MG
   Peking Union Medical College Hospital
      2021   Phase 2/Phase 3   NCT04728789   China
Avatrombopag 20 MG oral tablet
   Institute of Hematology & Blood Diseases Hospital
      2022   -   NCT05571332   China
Best practice
   Jennifer Woyach
      2020   Phase 1   NCT04439006   United States
Biospecimen collection
   City of Hope Medical Center
      2024   Phase 1   NCT05757310   United States
   Fred Hutchinson Cancer Center
      2025   Phase 2   NCT06752694   United States
   Thomas Jefferson University
      2021   Phase 2   NCT05031897   United States
BL-8040
   BioLineRx, Ltd.
      2015   Phase 2   NCT02462252   United States
Bone marrow ablation with stem cell support
   Case Comprehensive Cancer Center
      1998   Phase 2   NCT00003336   United States
Bone marrow aspirate
   City of Hope Medical Center
      2024   Phase 1   NCT05757310   United States
Bone marrow aspiration
   Fred Hutchinson Cancer Center
      2025   Phase 2   NCT06752694   United States
   Fred Hutchinson Cancer Research Center
      2006   Phase 1   NCT00354419   United States
Bone marrow aspiration and biopsy
   Thomas Jefferson University
      2021   Phase 2   NCT05031897   United States
Bone marrow biopsy
   City of Hope Medical Center
      2024   Phase 1   NCT05757310   United States
   Fred Hutchinson Cancer Center
      2025   Phase 2   NCT06752694   United States
Bone marrow derived mesenchymal stem cells
   Guangzhou General Hospital of Guangzhou Military Command
      2011   Phase 1/Phase 2   NCT01305694   China
Bone marrow transplant
   M.D. Anderson Cancer Center
      2006   Phase 1/Phase 2   NCT00474747   United States
   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
      2014   Phase 2   NCT02224872   United States
Bone marrow transplantation
   Fred Hutchinson Cancer Center
      2025   Phase 2   NCT06752694   United States
   Roswell Park Cancer Institute
      1998   Phase 3   NCT00004474   United States
BPX-501 cells
   Bellicum Pharmaceuticals, Inc.
      2017   Phase 2   EUCTR2014-000584-41-ES   Italy;Spain;United Kingdom
      2014   Phase 1;Phase 2   EUCTR2014-000584-41-IT   Italy;Spain;United Kingdom
      -   Phase 2   EUCTR2014-000584-41-GB   Italy;Spain;United Kingdom
Busilvex
   King's College Hospital NHS Foundation Trust
      2008   Phase 2   EUCTR2007-001657-26-GB   United Kingdom
Busulfan
   Case Comprehensive Cancer Center
      1998   Phase 2   NCT00003336   United States
   King's College Hospital NHS Foundation Trust
      2008   Phase 2   EUCTR2007-001657-26-GB   United Kingdom
   Masonic Cancer Center, University of Minnesota
      2018   Phase 2   NCT03579875   United States
   Memorial Sloan Kettering Cancer Center
      2009   Phase 2   NCT00987480   United States
   Peking University People's Hospital
      2023   Phase 4   NCT06069180   China
   Roswell Park Cancer Institute
      1998   Phase 2/Phase 3   NCT00003816   United States
   Shanghai Children's Medical Center affiliated to Shanghai Jiao Tong University School of Medicine
      2017   Phase 0   ChiCTR1900023509   China
   Sidney Kimmel Cancer Center at Thomas Jefferson University
      2012   Phase 2   NCT01760655   United States
      2011   Phase 2   NCT01384513   United States
   Texas Oncology Cancer Center
      2011   Phase 2   NCT01500161   United States
   The First Affiliated Hospital of Henan University of Science and Technology
      2023   Phase 0   ChiCTR2300077547   China
   University of California, San Francisco
      2005   -   NCT00295997   United States
   University of Rochester
      2015   Phase 1   NCT03016806   United States
Busulfan/fludarabine phosphate/tacrolimus/methotrexate/G-CSF
   University of California, San Francisco
      2002   Phase 2   NCT00516152   United States
Campath
   Baylor College of Medicine
      2002   Phase 2   NCT00578903   United States
   National Heart, Lung, and Blood Institute (NHLBI)
      2005   Phase 2   NCT00195624   United States
Campath 1H
   Masonic Cancer Center, University of Minnesota
      2007   Phase 2/Phase 3   NCT00455312   United States
Campath, chemo and/or TBI allo SCT
   David Rizzieri, MD
      1999   Phase 2   NCT00004143   United States
Campath-1H
   Beth Israel Deaconess Medical Center
      2002   Phase 2   NCT00533923   United States
   National Heart, Lung, and Blood Institute (NHLBI)
      2003   Phase 2   NCT00065260   United States
Carboplatin
   Roswell Park Cancer Institute
      1998   Phase 2/Phase 3   NCT00003816   United States
Carmustine
   Texas Oncology Cancer Center
      2011   Phase 2   NCT01500161   United States
Caspofungin acetate
   José Miguel Cisneros Herreros
      2012   Phase 3   EUCTR2011-005152-34-ES   Spain
CD3-depleted hematopoietic cell transplantation
   Asan Medical Center
      2012   Phase 2   NCT01759732   Korea, Republic of
CD34 stem cell selection therapy
   Diane George
      2013   Phase 1/Phase 2   NCT01966367   United States
CD3±CD19 depleted hematopoietic stem cell transplantation
   Asan Medical Center
      2009   Phase 1/Phase 2   NCT01105273   Korea, Republic of
CD45RA-depleted DLI
   St. Jude Children's Research Hospital
      2021   Phase 2   NCT04558736   United States
CD62L- TEM
   University College, London
      2019   Phase 1   NCT03836690   United Kingdom
CD7 CAR-T cells injection
   Zhejiang University
      2024   Early Phase 1   NCT06633328   China
Cefepime dihydrochloride monohydrate
   José Miguel Cisneros Herreros
      2012   Phase 3   EUCTR2011-005152-34-ES   Spain
Cell infusion
   Masonic Cancer Center, University of Minnesota
      2024   Phase 2   NCT06412497   United States
Chelation
   Novartis Pharmaceuticals
      2014   Phase 4   NCT01818726   Russian Federation
   The First Affiliated Hospital of Kunming Medical University
      2024   Phase 0   ChiCTR2400092421   China
Chemotherapy
   Vanderbilt University
      2009   -   NCT00993694   United States
Chinese herbal concoction twice A DAY FOR 6 months
   Singapore General Hospital
      2009   Phase 1/Phase 2   NCT01224496   Singapore
Ciclosporin
   Institute of Hematology & Blood Disease Hospital Chinese Academy of Medical Sciences
      2021   Phase 0   ChiCTR2100045322   China
   Jiangsu HengRui Medicine Co., Ltd.
      2023   Phase 2   NCT05797623   China
   Jiangsu Province Hospital
      2020   Phase 4   ChiCTR2100045895   China
   Karolinska Institutet
      2007   -   EUCTR2006-006577-25-SE   Finland;Sweden
   Peking Union Medical College Hospital
      2023   Phase 4   NCT06009497   China
      2023   Phase 2   NCT06004752   China
      2023   Phase 4   NCT05996393   China
Ciclosporin soft capsule
   Jiangsu HengRui Medicine Co., Ltd.
      2020   Phase 1   NCT05088174   China
Ciclosporina
   NOVARTIS PHARMA AG
      2019   Phase 2   EUCTR2016-002814-29-IT   Brazil;Hong Kong;Hungary;India;Italy;Korea, Democratic People's Republic of;Mexico;Netherlands;Spain;Thailand;Turkey
Ciclosporine
   Blood Diseases Hospital, Chinese Academy of Medical Sciences
      2015   Phase 1 study   ChiCTR-IPR-14005720   China
   EBMT (European group for Blood and Marrow Transplantation)
      2008   Phase 2   EUCTR2007-000902-55-FR   France;Germany;United Kingdom
Cilastatin
   VU University Medical Center
      2015   Phase 4   EUCTR2014-001546-25-NL   Netherlands
Ciprofloxacin
   José Miguel Cisneros Herreros
      2012   Phase 3   EUCTR2011-005152-34-ES   Spain
Clinimacs
   St. Jude Children's Research Hospital
      2021   Phase 2   NCT04558736   United States
Clinimacs device
   Memorial Sloan Kettering Cancer Center
      2009   Phase 2   NCT00987480   United States
Clofarabine
   Texas Oncology Cancer Center
      2011   Phase 2   NCT01500161   United States
CM313(SC) injection
   Keymed Biosciences Co.Ltd
      2025   Phase 1/Phase 2   NCT06791824   China
Cohort 1: hatg, CSA, epag DAY 14 TO month 6
   National Heart, Lung, and Blood Institute (NHLBI)
      2012   Phase 1/Phase 2   NCT01623167   United States
Cohort 2: hatg, CSA, epag DAY 14 TO month 3
   National Heart, Lung, and Blood Institute (NHLBI)
      2012   Phase 1/Phase 2   NCT01623167   United States
Cohort 3: hatg, CSA (dose reduced), epag DAY 1 TO month 6
   National Heart, Lung, and Blood Institute (NHLBI)
      2012   Phase 1/Phase 2   NCT01623167   United States
Combination OF thrombopoietin mimetic and cyclosporin A
   Safaa AA Khaled
      2019   Phase 4   NCT03896971   Egypt
Computed tomography
   Fred Hutchinson Cancer Center
      2025   Phase 2   NCT06752694   United States
Cord blood
   Jinan Military General Hospital
      2017   Phase 4   NCT02838992   China
   Kobe University Graduate School of Medicine
      2010   -   JPRN-UMIN000004264   Japan
   Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
      2016   Phase 4   NCT02745717   China
   The Second Affiliated Hospital of Xi'an Jiaotong University (Xibei Hospital)
      2021   Phase 0   ChiCTR2100047288   China
Cord blood infusion
   University of Rochester
      2015   Phase 1   NCT03016806   United States
Cord blood transplant
   National Heart, Lung, and Blood Institute (NHLBI)
      2012   Phase 1/Phase 2   NCT01553461   United States
Cord blood units
   Center for International Blood and Marrow Transplant Research
      2011   -   NCT01351545   United States
   National Heart, Lung, and Blood Institute (NHLBI)
      2015   Phase 2   NCT01861093   United States
Creatinine
   Ishiyama Ken
      2019   Phase 2   JPRN-jRCTs071190032   -
CSA
   Cooperative study between the West Japan Hematology Study Group and Clinical Research Support Center Kyushu
      2017   -   JPRN-UMIN000030453   Japan
   European Group for Blood and Marrow Transplantation
      2015   Phase 3   NCT02099747   France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
   Federal Research Institute of Pediatric Hematology, Oncology and Immunology
      2016   Phase 3   NCT03413306   Russian Federation
   Institute of Hematology & Hospital of Blood Diseases, Chinese Academy of Medical Sciences
      2019   Phase 0   ChiCTR1900027553   China
   Ishiyama Ken
      2019   Phase 2   JPRN-jRCTs071190032   -
   Jiangsu Province Hospital
      2020   Phase 4   ChiCTR2100045895   China
   Jinan Military General Hospital
      2017   Phase 4   NCT02838992   China
   Karolinska Institutet
      2007   -   EUCTR2006-006577-25-SE   Finland;Sweden
   National Heart, Lung, and Blood Institute (NHLBI)
      2003   Phase 2   NCT00065260   United States
   Novartis Pharmaceuticals
      2020   Phase 2   NCT04328727   China;Japan;Korea, Republic of;Taiwan
      2017   Phase 2   NCT03025698   Hong Kong;Netherlands;Portugal;Russian Federation;Thailand;United Kingdom;United States
      2015   Phase 2   NCT02404025   Japan
   Peking Union Medical College Hospital
      2025   Phase 2   NCT06802055   China
   The Second Affiliated Hospital of Xi'an Jiaotong University (Xibei Hospital)
      2021   Phase 0   ChiCTR2100047288   China
   Tianjin Medical University General Hospital
      2023   -   ChiCTR2300072983   China
      2023   -   ChiCTR2300067615   Tianjin
CSA+ATG+herombopag
   Peking Union Medical College Hospital
      2023   Phase 4   NCT06009965   China
CSA+herombopag
   Peking Union Medical College Hospital
      2023   Phase 4   NCT06009965   China
CY-ATG
   Cooperative Study Group A for Hematology
      2010   Phase 3   NCT01145976   Korea, Republic of
Cyclophosphamide
   Asan Medical Center
      2012   Phase 2   NCT01759732   Korea, Republic of
      2009   Phase 1/Phase 2   NCT01105273   Korea, Republic of
   Beth Israel Deaconess Medical Center
      2002   Phase 2   NCT00533923   United States
      1999   Phase 2   NCT00636909   -
   Boston Children's Hospital
      2023   Phase 3   NCT05600426   Canada;United States
   Cancer Hospital Affiliated to Zhengzhou University-He'nan Cancer Hospital
      2019   Phase 0   ChiCTR1900026462   China
   Case Comprehensive Cancer Center
      2002   Phase 1   NCT00054236   United States
      2000   Phase 2   NCT00006379   United States
      1998   Phase 2   NCT00003336   United States
   City of Hope Medical Center
      2024   Phase 1   NCT05757310   United States
   Fred Hutchinson Cancer Research Center
      2006   Phase 2   NCT00358657   United States
      2006   Phase 1   NCT00354419   United States
      2006   Phase 2   NCT00343785   Canada;United States
   H. Lee Moffitt Cancer Center and Research Institute
      1996   Phase 2   NCT00005852   -
   Kanto Study Group for Cell Therapy
      2011   Phase 2   JPRN-UMIN000006071   Japan
   M.D. Anderson Cancer Center
      2019   Phase 1/Phase 2   NCT03622788   United States
      2017   Phase 1   NCT02960646   United States
      2006   Phase 1/Phase 2   NCT00474747   United States
      2000   -   NCT00427336   United States
   Masonic Cancer Center, University of Minnesota
      2024   Phase 2   NCT06412497   United States
      2018   Phase 2   NCT03579875   United States
      2015   -   NCT02162420   United States
      2007   Phase 2/Phase 3   NCT00455312   United States
   Medical College of Wisconsin
      2017   Phase 2   NCT02918292   United States
   Memorial Sloan Kettering Cancer Center
      2018   Phase 1   NCT03531736   United States
      2009   Phase 2   NCT00987480   United States
      1995   Phase 2   NCT00002718   United States
   Michael Pulsipher
      2016   -   NCT02845596   United States
   National Center for Research Resources (NCRR)
      1995   Phase 2   NCT00004323   United States
   National Heart, Lung, and Blood Institute (NHLBI)
      2019   Phase 2   NCT03520647   United States
      2010   Phase 1/Phase 2   NCT01193283   United States
      2010   Phase 1/Phase 2   NCT01187017   United States
      1997   Phase 2   NCT00001626   United States
   National Institute of Blood and Marrow Transplant (NIBMT), Pakistan
      2018   Phase 2   NCT03955601   Pakistan
   Northside Hospital, Inc.
      2016   Phase 2   NCT02828592   United States
   Northwestern Memorial Hospital
      2001   -   NCT00017654   United States
   Roswell Park Cancer Institute
      2017   Phase 2   NCT03333486   United States
      2017   Phase 1/Phase 2   NCT03192397   United States
      2002   Phase 2   NCT00053989   United States
      1998   Phase 3   NCT00004474   United States
      1998   Phase 2/Phase 3   NCT00003816   United States
   Sidney Kimmel Cancer Center at Thomas Jefferson University
      2015   Phase 2   NCT02566304   United States
      2012   Phase 2   NCT01760655   United States
      2011   Phase 2   NCT01384513   United States
      2010   Phase 2   NCT01350245   United States
   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
      2016   Phase 2   NCT02833805   United States
      2014   Phase 2   NCT02224872   United States
      1996   Phase 2   NCT00004464   United States
   St. Jude Children's Research Hospital
      2021   Phase 2   NCT04558736   United States
   The First Affiliated Hospital of Henan University of Science and Technology
      2023   Phase 0   ChiCTR2300077547   China
   The Korean Society of Pediatric Hematology Oncology
      2006   Phase 2   NCT00737685   Korea, Republic of
   Thomas Jefferson University
      2021   Phase 2   NCT05031897   United States
   University of Alabama at Birmingham
      2013   Phase 2   NCT02065154   United States
   University of California, San Francisco
      2005   -   NCT00295997   United States
   University of Rochester
      2015   Phase 1   NCT03016806   United States
   Xiangya Hosptial of Central South University
      2017   -   ChiCTR-ONC-17012896   China
Cyclophosphamide 100MG
   Medical College of Wisconsin
      2006   Phase 1/Phase 2   NCT00326417   United States
Cyclophosphamide 150MG
   Medical College of Wisconsin
      2006   Phase 1/Phase 2   NCT00326417   United States
Cyclophosphamide 50MG
   Medical College of Wisconsin
      2006   Phase 1/Phase 2   NCT00326417   United States
Cyclophosphamide added TO standard immunosuppressive therapy with herombopag
   Institute of Hematology & Blood Diseases Hospital, China
      2023   Phase 2   NCT05975996   China
Cyclophosphamide monohydrate
   King's College Hospital NHS Foundation Trust
      2008   Phase 2   EUCTR2007-001657-26-GB   United Kingdom
Cyclophosphamide, fludarabine, rabbit ATG
   City of Hope Medical Center
      2009   -   NCT01129323   United States
Cyclophosphamide, fludarabine, thymoglobulin
   The Korean Society of Pediatric Hematology Oncology
      2008   Phase 2   NCT00882323   Korea, Republic of
Cyclophosphamide,campath IH and TBI
   Mayo Clinic
      2007   Phase 1   NCT00578266   United States
Cyclophosphamide,cyclosporine A
   Xiaofan Zhu
      2012   Phase 4   NCT01995331   China
Cyclosporin
   Beth Israel Deaconess Medical Center
      2002   Phase 2   NCT00533923   United States
   The First Affiliated Hospital of Zhengzhou University
      2016   -   ChiCTR-IOR-16008738   China
Cyclosporin A
   EBMT (European group for Blood and Marrow Transplantation)
      2008   Phase 2   EUCTR2007-000902-55-FR   France;Germany;United Kingdom
   Peking Union Medical College Hospital
      2025   Phase 2   NCT06802055   China
      2024   Phase 4   NCT06525948   China
Cyclosporine
   Beth Israel Deaconess Medical Center
      1999   Phase 2   NCT00636909   -
   BioLineRx, Ltd.
      2015   Phase 2   NCT02462252   United States
   Boston Children's Hospital
      2023   Phase 3   NCT05600426   Canada;United States
   Cooperative study between the West Japan Hematology Study Group and Clinical Research Support Center Kyushu
      2017   -   JPRN-UMIN000030453   Japan
   Federico II University
      2006   Phase 2   NCT00895739   Italy
   Fred Hutchinson Cancer Center
      2025   Phase 2   NCT06752694   United States
   Fred Hutchinson Cancer Research Center
      2006   Phase 1   NCT00354419   United States
      2006   Phase 2   NCT00343785   Canada;United States
   H. Lee Moffitt Cancer Center and Research Institute
      1996   Phase 2   NCT00005852   -
   Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
      2021   Phase 2   ChiCTR2100043229   China
   Institute of Hematology & Hospital of Blood Diseases, Chinese Academy of Medical Sciences
      2019   Phase 0   ChiCTR1900027553   China
   Institute of Hematology & Hospital of Blood Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College
      2021   Phase 4   ChiCTR2000041485   China
   Jinhua people's Hospital
      2015   Phase 2-3   ChiCTR1900028153   -
   M.D. Anderson Cancer Center
      2012   Phase 2   NCT01624805   United States
      2005   Phase 2   NCT00806598   United States
   Memorial Sloan Kettering Cancer Center
      2009   Phase 2   NCT00987480   United States
   Michael Pulsipher
      2016   -   NCT02845596   United States
   National Center for Research Resources (NCRR)
      1995   Phase 2   NCT00004323   United States
   National Heart, Lung, and Blood Institute (NHLBI)
      2020   Phase 2   NCT04304820   United States
      2010   Phase 1/Phase 2   NCT01193283   United States
      2009   Phase 2   NCT00944749   United States
      2005   Phase 2   NCT00260689   United States
      2005   Phase 2   NCT00195624   United States
      2000   Phase 2   NCT00005935   United States
      1997   Phase 2   NCT00001626   United States
   Northwestern Memorial Hospital
      2001   -   NCT00017654   United States
   Office of Rare Diseases (ORD)
      2006   Phase 1/Phase 2   NCT00319878   United States
   Peking Union Medical College Hospital
      2024   Phase 4   NCT06424639   China
   The Cleveland Clinic
      2005   Phase 2   NCT01231841   United States
   The First Affiliated Hospital of Zhejiang Chinese Medical University(Zhejiang Provincial Hospital of Chinese Medicine)
      2024   Phase 2   ChiCTR2500096280   China
   Zhejiang Provincial Hospital of Traditional Chinese Medicine
      2021   -   ChiCTR2100050948   China
Cyclosporine A
   Amgen
      2023   Phase 2   NCT05323617   -
   National Heart, Lung, and Blood Institute (NHLBI)
      2000   Phase 2   NCT00001964   United States
   Novartis Pharmaceuticals
      2020   Phase 2   NCT04328727   China;Japan;Korea, Republic of;Taiwan
   Shimonaga Contact Masahiro
      2023   Phase 2   JPRN-jRCT2031230178   -
Cyclosporine oral product
   Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
      2016   Phase 4   NCT02745717   China
Cyclosporins
   Boston Children's Hospital
      2012   Phase 2   NCT01659606   Norway;Sweden;United States
   Shengyun Lin
      2018   -   NCT03218657   China
Cytarabine
   Memorial Sloan Kettering Cancer Center
      1995   Phase 2   NCT00002718   United States
   Texas Oncology Cancer Center
      2011   Phase 2   NCT01500161   United States
   The Second Affiliated Hospital of Xi'an Jiaotong University (Xibei Hospital)
      2021   Phase 0   ChiCTR2100047288   China
Cytokine-treated veto cells
   M.D. Anderson Cancer Center
      2019   Phase 1/Phase 2   NCT03622788   United States
Cytoxan
   Baylor College of Medicine
      2002   Phase 2   NCT00578903   United States
Daclizumab
   Neal Young, M.D.
      1999   Phase 2   NCT00001962   United States
Danazol
   Institute of Hematology & Hospital of Blood Diseases, Chinese Academy of Medical Sciences
      2019   Phase 0   ChiCTR1900027553   China
   Institute of Hematology & Hospital of Blood Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College
      2021   Phase 4   ChiCTR2000041485   China
   National Heart, Lung, and Blood Institute (NHLBI)
      2011   Phase 1/Phase 2   NCT01441037   United States
Dapsone
   Vanderbilt University
      2009   -   NCT00993694   United States
Daratumumab
   Institute of Hematology & Blood Diseases Hospital, China
      2023   Phase 1   NCT05832216   China
   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
      2024   Early Phase 1   NCT06398457   United States
Decitabine
   The Second Affiliated Hospital of Xi'an Jiaotong University (Xibei Hospital)
      2021   Phase 0   ChiCTR2100047288   China
Desferasirox
   Novartis Pharmaceuticals
      2011   Phase 4   NCT01546415   China
Dextrose
   Kobe University Graduate School of Medicine
      2010   -   JPRN-UMIN000004264   Japan
Diagnostic imaging
   Thomas Jefferson University
      2021   Phase 2   NCT05031897   United States
DNA analysis
   City of Hope Medical Center
      2010   -   NCT01199562   United States
   Fred Hutchinson Cancer Research Center
      2006   Phase 1   NCT00354419   United States
      2006   Phase 2   NCT00343785   Canada;United States
Donor derived G-CSF mobilized PBC
   National Heart, Lung, and Blood Institute (NHLBI)
      2010   Phase 2   NCT01174108   United States
Donor lymphocyte infusion
   Sidney Kimmel Cancer Center at Thomas Jefferson University
      2011   Phase 2   NCT01384513   United States
      2010   Phase 2   NCT01350245   United States
   Thomas Jefferson University
      2021   Phase 2   NCT05031897   United States
Donor mobilized pbsc infusion
   Masonic Cancer Center, University of Minnesota
      2018   Phase 2   NCT03579875   United States
Early retreatment with ATG
   European Society for Blood and Marrow Transplantation
      2001   Phase 3   NCT01163942   Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;Switzerland;United Kingdom
Echocardiography
   Fred Hutchinson Cancer Center
      2025   Phase 2   NCT06752694   United States
Edta
   Kobe University Graduate School of Medicine
      2010   -   JPRN-UMIN000004264   Japan
Eltrombopag
   Assiut University
      2024   Phase 3   NCT06493981   -
      2017   Phase 4   NCT03243656   Egypt
   B. Höchsmann
      2015   Phase 2/Phase 3   NCT02773225   Germany
   European Group for Blood and Marrow Transplantation
      2015   Phase 3   NCT02099747   France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
   European Society for Blood and Marrow Transplantation
      2016   Phase 3   EUCTR2014-000363-40-NL   Netherlands;Spain
      2015   -   EUCTR2014-000363-40-ES   Spain
   Federal Research Institute of Pediatric Hematology, Oncology and Immunology
      2016   Phase 3   NCT03413306   Russian Federation
   Melbourne Health
      2024   Phase 1/Phase 2   NCT06607367   Australia
   NOVARTIS PHARMA AG
      2019   Phase 2   EUCTR2016-002814-29-IT   Brazil;Hong Kong;Hungary;India;Italy;Korea, Democratic People's Republic of;Mexico;Netherlands;Spain;Thailand;Turkey
   National Heart, Lung, and Blood Institute (NHLBI)
      2020   Phase 2   NCT04304820   United States
      2013   Phase 2   NCT01891994   United States
      2011   Phase 2   NCT01328587   United States
      2009   Phase 2   NCT00922883   United States
   Novartis Farmacéutica, S.A
      2017   Phase 2   EUCTR2016-002814-29-ES   Brazil;Canada;France;Hong Kong;Hungary;India;Italy;Korea, Republic of;Mexico;Netherlands;Qatar;Spain;Turkey
   Novartis Pharma AG
      2019   Phase 2   EUCTR2015-003166-91-GB   Hong Kong;Netherlands;Portugal;Russian Federation;Thailand;United Kingdom;United States
      2018   Phase 2   EUCTR2015-003166-91-NL   Hong Kong;Netherlands;Portugal;Russian Federation;Thailand;United Kingdom;United States
      2017   Phase 2   EUCTR2016-002814-29-NL   Brazil;Hong Kong;Hungary;India;Italy;Korea, Republic of;Mexico;Netherlands;Spain;Thailand;Turkey
      2017   Phase 2   EUCTR2016-002814-29-HU   Brazil;France;Hong Kong;Hungary;India;Italy;Korea, Republic of;Mexico;Netherlands;Spain;Turkey
      2017   Phase 2   EUCTR2015-003166-91-PT   Hong Kong;Netherlands;Portugal;Russian Federation;Thailand;United Kingdom;United States
   Novartis Pharmaceuticals
      2024   -   NCT06287268   Japan
      2020   Phase 2   NCT04328727   China;Japan;Korea, Republic of;Taiwan
      2017   Phase 2   NCT03025698   Hong Kong;Netherlands;Portugal;Russian Federation;Thailand;United Kingdom;United States
      2015   Phase 2   NCT02404025   Japan
   The First Affiliated Hospital of Zhejiang Medical University
      2021   Phase 4   ChiCTR2100054957   China
   The First Affiliated Hospital of Zhejiang University of Traditional Chinese Medicine
      2022   Phase 4   ChiCTR2200060098   China
   Tianjin Medical University General Hospital
      2023   -   ChiCTR2300067615   Tianjin
   University of Utah
      2012   Phase 2   NCT01703169   United States
Eltrombopag 12.5 MG
   Novartis Pharmaceuticals
      2014   Phase 2   NCT02148133   Japan
Eltrombopag 25 MG
   Novartis Pharmaceuticals
      2019   Phase 2   NCT03988608   China
      2014   Phase 2   NCT02148133   Japan
Eltrombopag olamine
   Universitätsklinikum Ulm
      2015   Phase 2;Phase 3   EUCTR2014-000174-19-DE   France;Germany;Switzerland
   Universitätsklinikum Ulm (Clinique universitaire dÚlm)
      2021   Phase 2;Phase 3   EUCTR2014-000174-19-FR   France;Germany;Italy;Netherlands;Switzerland;United Kingdom
Emapalumab
   Memorial Sloan Kettering Cancer Center
      2024   Phase 2   NCT06430788   United States
Enbrel*SC 4FL 25MG+4SIR 1ML
   ISTITUTO GIANNINA GASLINI
      2009   -   EUCTR2009-012746-23-IT   Italy
      2005   -   EUCTR2004-004914-18-IT   Italy
Etanercept
   ISTITUTO GIANNINA GASLINI
      2009   -   EUCTR2009-012746-23-IT   Italy
      2005   -   EUCTR2004-004914-18-IT   Italy
ETB115
   NOVARTIS PHARMA AG
      2019   Phase 2   EUCTR2016-002814-29-IT   Brazil;Hong Kong;Hungary;India;Italy;Korea, Democratic People's Republic of;Mexico;Netherlands;Spain;Thailand;Turkey
   Novartis Farmacéutica, S.A
      2017   Phase 2   EUCTR2016-002814-29-ES   Brazil;Canada;France;Hong Kong;Hungary;India;Italy;Korea, Republic of;Mexico;Netherlands;Qatar;Spain;Turkey
   Novartis Pharma AG
      2019   Phase 2   EUCTR2015-003166-91-GB   Hong Kong;Netherlands;Portugal;Russian Federation;Thailand;United Kingdom;United States
      2018   Phase 2   EUCTR2015-003166-91-NL   Hong Kong;Netherlands;Portugal;Russian Federation;Thailand;United Kingdom;United States
      2017   Phase 2   EUCTR2016-002814-29-NL   Brazil;Hong Kong;Hungary;India;Italy;Korea, Republic of;Mexico;Netherlands;Spain;Thailand;Turkey
      2017   Phase 2   EUCTR2016-002814-29-HU   Brazil;France;Hong Kong;Hungary;India;Italy;Korea, Republic of;Mexico;Netherlands;Spain;Turkey
      2017   Phase 2   EUCTR2015-003166-91-PT   Hong Kong;Netherlands;Portugal;Russian Federation;Thailand;United Kingdom;United States
Etoposide
   Roswell Park Cancer Institute
      1998   Phase 2/Phase 3   NCT00003816   United States
   Texas Oncology Cancer Center
      2011   Phase 2   NCT01500161   United States
EX vivo immunotherapy
   Shenzhen Zhongxing Yangfan Biotech Co. Ltd.
      2002   Phase 1/Phase 2   NCT00399971   China
Exercise intervention
   Children's Hospital of Philadelphia
      2023   Phase 2   NCT05194397   United States
Extension cohort
   National Heart, Lung, and Blood Institute (NHLBI)
      2012   Phase 1/Phase 2   NCT01623167   United States
Filgrastim
   Asan Medical Center
      2012   Phase 2   NCT01759732   Korea, Republic of
      2009   Phase 1/Phase 2   NCT01105273   Korea, Republic of
   Case Comprehensive Cancer Center
      2002   Phase 1   NCT00054236   United States
   Fred Hutchinson Cancer Research Center
      2006   Phase 1   NCT00354419   United States
   H. Lee Moffitt Cancer Center and Research Institute
      1996   Phase 2   NCT00005852   -
   M.D. Anderson Cancer Center
      2017   Phase 1   NCT02960646   United States
      2012   Phase 2   NCT01624805   United States
   Memorial Sloan Kettering Cancer Center
      1995   Phase 2   NCT00002718   United States
   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
      1996   Phase 2   NCT00004464   United States
   University of California, San Francisco
      2005   -   NCT00295997   United States
FK-506
   Baylor College of Medicine
      2002   Phase 2   NCT00578903   United States
   Karolinska Institutet
      2007   -   EUCTR2006-006577-25-SE   Finland;Sweden
Flow cytometry
   City of Hope Medical Center
      2010   -   NCT01199562   United States
   Fred Hutchinson Cancer Research Center
      2006   Phase 2   NCT00343785   Canada;United States
FLU-ATG
   Cooperative Study Group A for Hematology
      2010   Phase 3   NCT01145976   Korea, Republic of
FLU/CY/ATG or CY/ATG
   Peking University People's Hospital
      2023   Phase 4   NCT06069180   China
Fludarabine
   Asan Medical Center
      2012   Phase 2   NCT01759732   Korea, Republic of
      2009   Phase 1/Phase 2   NCT01105273   Korea, Republic of
   Beth Israel Deaconess Medical Center
      2002   Phase 2   NCT00533923   United States
      1999   Phase 2   NCT00636909   -
   Boston Children's Hospital
      2023   Phase 3   NCT05600426   Canada;United States
      2012   Phase 2   NCT01659606   Norway;Sweden;United States
   Fred Hutchinson Cancer Center
      2025   Phase 2   NCT06752694   United States
   GCP-ISS HE0403 group
      2004   Phase 1,2   JPRN-C000000356   Japan
   Kanto Study Group for Cell Therapy
      2011   Phase 2   JPRN-UMIN000006071   Japan
   M.D. Anderson Cancer Center
      2019   Phase 1/Phase 2   NCT03622788   United States
      2006   Phase 1/Phase 2   NCT00474747   United States
      2000   -   NCT00427336   United States
   Masonic Cancer Center, University of Minnesota
      2024   Phase 2   NCT06412497   United States
      2018   Phase 2   NCT03579875   United States
      2015   -   NCT02162420   United States
      2007   Phase 2/Phase 3   NCT00455312   United States
   Medical College of Wisconsin
      2017   Phase 2   NCT02918292   United States
      2006   Phase 1/Phase 2   NCT00326417   United States
   Memorial Sloan Kettering Cancer Center
      2018   Phase 1   NCT03531736   United States
      2009   Phase 2   NCT00987480   United States
   Michael Pulsipher
      2016   -   NCT02845596   United States
   National Heart, Lung, and Blood Institute (NHLBI)
      2010   Phase 1/Phase 2   NCT01187017   United States
   Northside Hospital, Inc.
      2016   Phase 2   NCT02828592   United States
   Peking University People's Hospital
      2018   -   NCT03821987   China
   Seoul National University Hospital
      2011   Phase 2   NCT01472055   Korea, Republic of
   Sidney Kimmel Cancer Center at Thomas Jefferson University
      2015   Phase 2   NCT02566304   United States
      2011   Phase 2   NCT01384513   United States
   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
      2016   Phase 2   NCT02833805   United States
      2014   Phase 2   NCT02224872   United States
   St. Jude Children's Research Hospital
      2021   Phase 2   NCT04558736   United States
   Texas Oncology Cancer Center
      2011   Phase 2   NCT01500161   United States
   The First Affiliated Hospital of Henan University of Science and Technology
      2023   Phase 0   ChiCTR2300077547   China
   The Korean Society of Pediatric Hematology Oncology
      2006   Phase 2   NCT00737685   Korea, Republic of
   Thomas Jefferson University
      2021   Phase 2   NCT05031897   United States
   University of Rochester
      2015   Phase 1   NCT03016806   United States
Fludarabine phosphate
   Case Comprehensive Cancer Center
      2002   Phase 1   NCT00054236   United States
      2000   Phase 2   NCT00006379   United States
   Fred Hutchinson Cancer Research Center
      2006   Phase 2   NCT00358657   United States
   King's College Hospital NHS Foundation Trust
      2008   Phase 2   EUCTR2007-001657-26-GB   United Kingdom
   M.D. Anderson Cancer Center
      2017   Phase 1   NCT02960646   United States
   Roswell Park Cancer Institute
      2017   Phase 2   NCT03333486   United States
      2017   Phase 1/Phase 2   NCT03192397   United States
      2012   Phase 2   NCT01529827   United States
      2009   -   NCT00856388   United States
      2002   Phase 2   NCT00053989   United States
      1998   Phase 2/Phase 3   NCT00003816   United States
   Sidney Kimmel Cancer Center at Thomas Jefferson University
      2012   Phase 2   NCT01760655   United States
   University of California, San Francisco
      2005   -   NCT00295997   United States
Fludarabine, cyclophosphamide
   St. Jude Children's Research Hospital
      2002   -   NCT00186797   United States
Fludarabine/ melphalan
   University of Illinois at Chicago
      2000   -   NCT01499147   United States
Fludarabine/busulfan
   University of Illinois at Chicago
      2000   -   NCT01499147   United States
Foscarnet
   The First Affiliated Hospital of Zhejiang University School of Medicine
      2020   Phase 0   ChiCTR2000031933   China
Foscarnet sodium
   City of Hope Medical Center
      2010   -   NCT01199562   United States
G-CSF
   Beth Israel Deaconess Medical Center
      1999   Phase 2   NCT00636909   -
   European Society for Blood and Marrow Transplantation
      2001   Phase 3   NCT01163942   Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;Switzerland;United Kingdom
   Institute of Hematology & Hospital of Blood Diseases, Chinese Academy of Medical Sciences
      2019   Phase 0   ChiCTR1900027553   China
   M.D. Anderson Cancer Center
      2005   Phase 2   NCT00806598   United States
   Masonic Cancer Center, University of Minnesota
      2018   Phase 2   NCT03579875   United States
   Medical College of Wisconsin
      2017   Phase 2   NCT02918292   United States
   National Heart, Lung, and Blood Institute (NHLBI)
      2001   Phase 1   NCT00011830   United States
   St. Jude Children's Research Hospital
      2021   Phase 2   NCT04558736   United States
Ganciclovir
   City of Hope Medical Center
      2010   -   NCT01199562   United States
Glycine
   EBMT (European group for Blood and Marrow Transplantation)
      2008   Phase 2   EUCTR2007-000902-55-FR   France;Germany;United Kingdom
      2007   Phase 2   EUCTR2007-000902-55-GB   France;Germany;United Kingdom
GM-CSF
   Beth Israel Deaconess Medical Center
      2002   Phase 2   NCT00533923   United States
Graft-versus-tumor induction therapy
   Case Comprehensive Cancer Center
      2000   Phase 2   NCT00006379   United States
   Roswell Park Cancer Institute
      2002   Phase 2   NCT00053989   United States
   University of California, San Francisco
      2005   -   NCT00295997   United States
Granulocyte colony-stimulating factor
   Fred Hutchinson Cancer Center
      2025   Phase 2   NCT06752694   United States
Gvhd prophylaxis
   Assiut University
      2019   Phase 2/Phase 3   NCT03295058   -
   Kobe University Graduate School of Medicine
      2010   -   JPRN-UMIN000004264   Japan
Haplo hsct
   Medical College of Wisconsin
      2017   Phase 2   NCT02918292   United States
Haplo/cord transplant
   Joanne Kurtzberg, MD
      2007   Phase 1/Phase 2   NCT00673114   United States
Haploidentical donor bone marrow transplant
   Medical College of Wisconsin
      2025   Phase 2   NCT06517641   United States
Haploidentical hematopoietic cell transplantation
   City of Hope Medical Center
      2024   Phase 1   NCT05757310   United States
   Johns Hopkins All Children's Hospital
      2020   Phase 2   NCT04356469   United States
Hatg
   BioLineRx, Ltd.
      2015   Phase 2   NCT02462252   United States
   European Group for Blood and Marrow Transplantation
      2015   Phase 3   NCT02099747   France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
   Novartis Pharmaceuticals
      2017   Phase 2   NCT03025698   Hong Kong;Netherlands;Portugal;Russian Federation;Thailand;United Kingdom;United States
Hematopoietic cell transplantation
   Thomas Jefferson University
      2021   Phase 2   NCT05031897   United States
Heparin
   Alberta Children's Hospital
      2011   Phase 3   NCT01343680   Canada
Herombopag
   Institute of Hematology & Blood Diseases Hospital, China
      2022   Phase 2   NCT05660785   China
Hetrombopag
   Institute of Hematology & Blood Diseases Hospital, China
      2024   Phase 4   ChiCTR2400088990   China
   Peking Union Medical College Hospital
      2021   Phase 2/Phase 3   NCT05018936   China
   Tianjin Medical University General Hospital
      2023   -   ChiCTR2300072983   China
   Wuhan Union Hospital, China
      2022   -   NCT05333861   China
Hetrombopag olamine
   Jiangsu HengRui Medicine Co., Ltd.
      2019   Phase 3   NCT04961710   China
Hetrombopag olamine tablet
   Jiangsu HengRui Medicine Co., Ltd.
      2021   Phase 1   NCT05088655   China
      2020   Phase 1   NCT05088642   China
      2020   Phase 1   NCT05088174   China
Hetrombopag olamine+standard therapy
   Jiangsu HengRui Medicine Co., Ltd.
      2019   Phase 3   NCT03825744   China
Horse ANTI-thymocyte globulin
   BioLineRx, Ltd.
      2015   Phase 2   NCT02462252   United States
   Boston Children's Hospital
      2023   Phase 3   NCT05600426   Canada;United States
   Michael Pulsipher
      2016   -   NCT02845596   United States
Horse-ANTI-thymocyte-globulin
   National Heart, Lung, and Blood Institute (NHLBI)
      2020   Phase 2   NCT04304820   United States
HPC, A infusion
   St. Jude Children's Research Hospital
      2021   Phase 2   NCT04558736   United States
Human IGG4 isotype monoclonal (IL2-RG) antibody
   Regeneron Pharmaceuticals, Inc.
      2020   Phase 1;Phase 2   EUCTR2020-002031-29-GB   France;Korea, Republic of;United Kingdom;United States
      2020   Phase 1;Phase 2   EUCTR2020-002031-29-FR   France;Korea, Republic of;United Kingdom;United States
Human placental derived stem cell
   New York Medical College
      2013   Phase 1   NCT01586455   United States
Human umbilical CORD-derived mscs and cyclosporin A
   Shandong University
      2010   Phase 2   NCT01182662   China
Hyaluronidase
   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
      2024   Early Phase 1   NCT06398457   United States
Ibrutinib
   Jennifer Woyach
      2020   Phase 1   NCT04439006   United States
ICL670
   Novartis Pharmaceuticals
      2014   Phase 4   NCT01818726   Russian Federation
Imipenem / cilastatine
   VU University Medical Center
      2015   Phase 4   EUCTR2014-001546-25-NL   Netherlands
Imipenem-cilastatine
   VU University Medical Center
      2015   Phase 4   EUCTR2014-001546-25-NL   Netherlands
IN vitro-treated bone marrow transplantation
   Memorial Sloan Kettering Cancer Center
      1995   Phase 2   NCT00002718   United States
IN vitro-treated peripheral blood stem cell transplantation
   Memorial Sloan Kettering Cancer Center
      1995   Phase 2   NCT00002718   United States
Infection prophylaxis and management
   City of Hope Medical Center
      2010   -   NCT01199562   United States
Intravenous bone marrow mesenchymal stem cells infusion
   University of Sao Paulo
      2011   Phase 1/Phase 2   NCT01297972   Brazil
Iron
   The First Affiliated Hospital of Kunming Medical University
      2024   Phase 0   ChiCTR2400092421   China
Iticitinib
   Incyte Corporation
      2018   -   NCT03906318   -
JH-DSA SEMI-quant screen and response score
   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
      2024   Early Phase 1   NCT06398457   United States
Laboratory biomarker analysis
   City of Hope Medical Center
      2010   -   NCT01199562   United States
   Fred Hutchinson Cancer Research Center
      2006   Phase 2   NCT00358657   United States
      2006   Phase 2   NCT00343785   Canada;United States
   M.D. Anderson Cancer Center
      2017   Phase 1   NCT02960646   United States
   Roswell Park Cancer Institute
      2017   Phase 2   NCT03333486   United States
      2017   Phase 1/Phase 2   NCT03192397   United States
      2012   Phase 2   NCT01529827   United States
   Sidney Kimmel Cancer Center at Thomas Jefferson University
      2015   Phase 2   NCT02566304   United States
      2012   Phase 2   NCT01760655   United States
   Vanderbilt-Ingram Cancer Center
      2009   -   NCT00960050   United States
Levamisole hydrochloride
   Shengyun Lin
      2018   -   NCT03218657   China
   The First affiliated Hospital of Zhejiang Chinese Medical University
      2017   -   ChiCTR-IOR-17011653   China
Levamisole+cyclosporin A+glucocorticoids
   Institute of Hematology & Blood Diseases Hospital
      2013   Phase 2   NCT01760096   China
      2012   Phase 2   NCT01642979   China
LO-ovral oral contraceptive pills
   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
      2007   Phase 1/Phase 2   NCT00556400   United States
Luspatercept
   Bing Han
      2022   Phase 2   NCT05399732   China
   Peking Union Medical College Hospital
      2024   Phase 4   NCT06424639   China
   The First Affiliated Hospital of Zhejiang Chinese Medical University
      2025   -   ChiCTR2500100409   China
Luspatercept combine with deferasirox
   The First Affiliated Hospital of Zhejiang Chinese Medical University
      2025   -   NCT06964971   China
Lusutrombopag
   Peking Union Medical College Hospital
      2024   Phase 4   NCT06426043   China
Mabcampath
   UNIVERSITA` DEGLI STUDI DI NAPOLI FEDERICO II
      2007   -   EUCTR2008-001151-22-IT   Italy
Management OF therapy complications
   City of Hope Medical Center
      2010   -   NCT01199562   United States
Mannitol
   EBMT (European group for Blood and Marrow Transplantation)
      2008   Phase 2   EUCTR2007-000902-55-FR   France;Germany;United Kingdom
      2007   Phase 2   EUCTR2007-000902-55-GB   France;Germany;United Kingdom
Matched unrelated donor hematopoetic stem cell transplant
   Boston Children's Hospital
      2023   Phase 3   NCT05600426   Canada;United States
Matched unrelated donor hematopoietic stem cell transplant
   Michael Pulsipher
      2016   -   NCT02845596   United States
Medical chart review
   Vanderbilt University
      2009   -   NCT00993694   United States
   Vanderbilt-Ingram Cancer Center
      2009   -   NCT00960050   United States
Melphalan
   Case Comprehensive Cancer Center
      1998   Phase 2   NCT00003336   United States
   King's College Hospital NHS Foundation Trust
      2008   Phase 2   EUCTR2007-001657-26-GB   United Kingdom
   M.D. Anderson Cancer Center
      2017   Phase 1   NCT02960646   United States
   Masonic Cancer Center, University of Minnesota
      2018   Phase 2   NCT03579875   United States
   Roswell Park Cancer Institute
      2012   Phase 2   NCT01529827   United States
      2009   -   NCT00856388   United States
      1998   Phase 2/Phase 3   NCT00003816   United States
   Texas Oncology Cancer Center
      2011   Phase 2   NCT01500161   United States
   Thomas Jefferson University
      2021   Phase 2   NCT05031897   United States
   University of Rochester
      2015   Phase 1   NCT03016806   United States
Melphalan hydrochloride
   Roswell Park Cancer Institute
      2017   Phase 1/Phase 2   NCT03192397   United States
Meropenem
   VU University Medical Center
      2015   Phase 4   EUCTR2014-001546-25-NL   Netherlands
Mesenchymal stem cells
   CHU Sart-Tilman
      2009   Phase 3   EUCTR2008-005594-35-BE   Belgium
   Guangzhou General Hospital of Guangzhou Military Command
      2013   Phase 2   NCT02247973   China
   Hebei Medical University
      2017   Phase 1   NCT03055078   China
   Navy General Hospital, Beijing
      2015   Phase 1/Phase 2   NCT02407470   China
Mesenchymal stromal cells
   National Research Center for Hematology, Russia
      2012   Phase 1/Phase 2   NCT01849237   Russian Federation
Mesna
   National Center for Research Resources (NCRR)
      1995   Phase 2   NCT00004323   United States
   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
      2014   Phase 2   NCT02224872   United States
   St. Jude Children's Research Hospital
      2021   Phase 2   NCT04558736   United States
   University of Rochester
      2015   Phase 1   NCT03016806   United States
Metformin
   Department of Hematology, Second Medical Center, Chinese PLA General Hospital
      2020   Phase 2   ChiCTR2000028833   China
Methadone
   University of Texas Southwestern Medical Center
      2025   Phase 3   NCT06940570   United States
Methotrexate
   Baylor College of Medicine
      2002   Phase 2   NCT00578903   United States
   Beth Israel Deaconess Medical Center
      1999   Phase 2   NCT00636909   -
   Boston Children's Hospital
      2023   Phase 3   NCT05600426   Canada;United States
   Fred Hutchinson Cancer Research Center
      2006   Phase 2   NCT00343785   Canada;United States
   Karolinska Institutet
      2007   -   EUCTR2006-006577-25-SE   Finland;Sweden
   Michael Pulsipher
      2016   -   NCT02845596   United States
   National Center for Research Resources (NCRR)
      1995   Phase 2   NCT00004323   United States
   Roswell Park Cancer Institute
      2012   Phase 2   NCT01529827   United States
   University of California, San Francisco
      2005   -   NCT00295997   United States
   Xiangya Hosptial of Central South University
      2017   -   ChiCTR-ONC-17012896   China
Methylprednisolone
   BioLineRx, Ltd.
      2015   Phase 2   NCT02462252   United States
   Case Comprehensive Cancer Center
      2002   Phase 1   NCT00054236   United States
      1998   Phase 2   NCT00003336   United States
   H. Lee Moffitt Cancer Center and Research Institute
      1996   Phase 2   NCT00005852   -
   Ishiyama Ken
      2019   Phase 2   JPRN-jRCTs071190032   -
   M.D. Anderson Cancer Center
      2012   Phase 2   NCT01624805   United States
      2005   Phase 2   NCT00806598   United States
   Masonic Cancer Center, University of Minnesota
      2018   Phase 2   NCT03579875   United States
      2007   Phase 2/Phase 3   NCT00455312   United States
   Memorial Sloan Kettering Cancer Center
      1995   Phase 2   NCT00002718   United States
   National Center for Research Resources (NCRR)
      1995   Phase 2   NCT00004323   United States
   Northwestern Memorial Hospital
      2001   -   NCT00017654   United States
   Roswell Park Cancer Institute
      2002   Phase 2   NCT00053989   United States
   The First Affiliated Hospital with Nanjing Medical University
      2024   Phase 3   ChiCTR2400087735   China
Miltenyi CD34 reagent system
   National Heart, Lung, and Blood Institute (NHLBI)
      2010   Phase 2   NCT01174108   United States
Miltenyi clinimacs(R) CD34 reagent system
   National Heart, Lung, and Blood Institute (NHLBI)
      2017   Phase 1/Phase 2   NCT03173937   United States
MMF
   Kobe University Graduate School of Medicine
      2010   -   JPRN-UMIN000004264   Japan
   Medical College of Wisconsin
      2017   Phase 2   NCT02918292   United States
   National Heart, Lung, and Blood Institute (NHLBI)
      2000   Phase 2   NCT00001964   United States
   Peking University People's Hospital
      2024   Phase 1/Phase 2   NCT06279494   -
   Sidney Kimmel Cancer Center at Thomas Jefferson University
      2010   Phase 2   NCT01350245   United States
Modified transplantation system
   Hematology department of the 920th hospital
      2024   Phase 2   NCT06378060   China
MPA
   Kobe University Graduate School of Medicine
      2010   -   JPRN-UMIN000004264   Japan
MSC
   CHU Sart-Tilman
      2009   Phase 3   EUCTR2008-005594-35-BE   Belgium
   Navy General Hospital, Beijing
      2015   Phase 1/Phase 2   NCT02407470   China
MSC+ATG
   Chinese Academy of Medical Sciences
      2013   Phase 4   NCT02218437   China
MTX
   Karolinska Institutet
      2007   -   EUCTR2006-006577-25-SE   Finland;Sweden
Multigated acquisition scan
   Fred Hutchinson Cancer Center
      2025   Phase 2   NCT06752694   United States
Muromonab-CD3
   H. Lee Moffitt Cancer Center and Research Institute
      1996   Phase 2   NCT00005852   -
Mycophenolate mofetil
   Boston Children's Hospital
      2012   Phase 2   NCT01659606   Norway;Sweden;United States
   Fred Hutchinson Cancer Center
      2025   Phase 2   NCT06752694   United States
   Fred Hutchinson Cancer Research Center
      2006   Phase 2   NCT00358657   United States
      2006   Phase 1   NCT00354419   United States
   Masonic Cancer Center, University of Minnesota
      2024   Phase 2   NCT06412497   United States
   Medical College of Wisconsin
      2017   Phase 2   NCT02918292   United States
   National Heart, Lung, and Blood Institute (NHLBI)
      2000   Phase 2   NCT00005935   United States
   Roswell Park Cancer Institute
      2017   Phase 1/Phase 2   NCT03192397   United States
      2012   Phase 2   NCT01529827   United States
      2002   Phase 2   NCT00053989   United States
   Sidney Kimmel Cancer Center at Thomas Jefferson University
      2015   Phase 2   NCT02566304   United States
      2012   Phase 2   NCT01760655   United States
      2011   Phase 2   NCT01384513   United States
      2010   Phase 2   NCT01350245   United States
   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
      2016   Phase 2   NCT02833805   United States
   Thomas Jefferson University
      2021   Phase 2   NCT05031897   United States
   University of California, San Francisco
      2005   -   NCT00295997   United States
Mycophenolic acid
   Kobe University Graduate School of Medicine
      2010   -   JPRN-UMIN000004264   Japan
Mycophenolic acid mofetil
   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
      2014   Phase 2   NCT02224872   United States
N acetyl L cysteine
   Peking University People's Hospital
      2024   Phase 2   NCT06518044   -
Nandrolone
   National Heart, Lung, and Blood Institute (NHLBI)
      1982   Phase 3   NCT00000597   -
Nandrolone decanoate
   University of Sao Paulo
      2014   Phase 1/Phase 2   NCT02055456   Brazil
Neoral
   Cooperative study between the West Japan Hematology Study Group and Clinical Research Support Center Kyushu
      2017   -   JPRN-UMIN000030453   Japan
   EBMT (European group for Blood and Marrow Transplantation)
      2008   Phase 2   EUCTR2007-000902-55-FR   France;Germany;United Kingdom
   Ishiyama Ken
      2019   Phase 2   JPRN-jRCTs071190032   -
Neoral 100 MG, capsule molle
   Amgen, Inc.
      2023   Phase 2   EUCTR2022-001257-22-FR   Brazil;France;United Kingdom;United States
Nicotinamide riboside
   Children's Hospital of Philadelphia
      2023   Phase 2   NCT05194397   United States
NON ATG conditioning regimen
   Assiut University
      2019   Phase 2/Phase 3   NCT03295058   -
Nonmyeloablative allogeneic hematopoietic stem cell transplantation
   Fred Hutchinson Cancer Research Center
      2006   Phase 2   NCT00358657   United States
   University of California, San Francisco
      2005   -   NCT00295997   United States
Normal saline
   Alberta Children's Hospital
      2011   Phase 3   NCT01343680   Canada
Noxafil gastro resistant tablets
   King's College Hospital NHS Foundation Trust
      2016   Phase 4   EUCTR2016-001223-31-GB   United Kingdom
Nplate
   Amgen, Inc.
      2023   Phase 2   EUCTR2022-001257-22-FR   Brazil;France;United Kingdom;United States
Obatoclax
   Gemin X
      2005   Phase 1   NCT00438178   Canada;United States
Omidubicel
   National Heart, Lung, and Blood Institute (NHLBI)
      2017   Phase 1/Phase 2   NCT03173937   United States
ONE ML contains horse ANTI-human T lymphocyte immunoglobulin (eatg) 50 MG
   Amgen, Inc.
      2023   Phase 2   EUCTR2022-001257-22-FR   Brazil;France;United Kingdom;United States
PCA
   University of Texas Southwestern Medical Center
      2025   Phase 3   NCT06940570   United States
PEG-RHG-CSF
   Institute of Hematology & Blood Diseases Hospital
      2022   -   NCT05531279   China
Pegfilgrastim
   M.D. Anderson Cancer Center
      2012   Phase 2   NCT01624805   United States
Pentostatin
   City of Hope Medical Center
      2024   Phase 1   NCT05757310   United States
Peripheral blood stem cell transplantation
   Case Comprehensive Cancer Center
      2000   Phase 2   NCT00006379   United States
   Fred Hutchinson Cancer Center
      2025   Phase 2   NCT06752694   United States
   M.D. Anderson Cancer Center
      2019   Phase 1/Phase 2   NCT03622788   United States
      2017   Phase 1   NCT02960646   United States
   Roswell Park Cancer Institute
      2017   Phase 2   NCT03333486   United States
      2012   Phase 2   NCT01529827   United States
      2002   Phase 2   NCT00053989   United States
   Sidney Kimmel Cancer Center at Thomas Jefferson University
      2015   Phase 2   NCT02566304   United States
      2012   Phase 2   NCT01760655   United States
      2011   Phase 2   NCT01384513   United States
   University of California, San Francisco
      2005   -   NCT00295997   United States
Peripheral blood stem cells
   National Heart, Lung, and Blood Institute (NHLBI)
      2019   Phase 2   NCT03520647   United States
PF-06462700
   Pfizer
      2020   Phase 3   NCT04350606   Japan
Polymerase chain reaction
   City of Hope Medical Center
      2010   -   NCT01199562   United States
Polymorphism analysis
   Fred Hutchinson Cancer Research Center
      2006   Phase 2   NCT00343785   Canada;United States
   Vanderbilt-Ingram Cancer Center
      2009   -   NCT00960050   United States
Posaconazole
   King's College Hospital NHS Trust
      2016   Phase 4   NCT02875743   United Kingdom
   Seoul National University Hospital
      2018   Phase 2   NCT03318159   Korea, Republic of
POST-transplant G-CSF
   Masonic Cancer Center, University of Minnesota
      2024   Phase 2   NCT06412497   United States
Prednisolone
   Ishiyama Ken
      2019   Phase 2   JPRN-jRCTs071190032   -
Prednisone
   Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
      2022   Phase 0   ChiCTR2200066279   China
Prograf
   Karolinska Institutet
      2007   -   EUCTR2006-006577-25-SE   Finland;Sweden
Protein expression analysis
   City of Hope Medical Center
      2010   -   NCT01199562   United States
Questionnaire administration
   City of Hope Medical Center
      2024   Phase 1   NCT05757310   United States
R-ATG
   National Heart, Lung, and Blood Institute (NHLBI)
      2003   Phase 2   NCT00065260   United States
   Novartis Pharmaceuticals
      2020   Phase 2   NCT04328727   China;Japan;Korea, Republic of;Taiwan
Rabbit
   Amgen, Inc.
      2023   Phase 2   EUCTR2022-001257-22-FR   Brazil;France;United Kingdom;United States
   Anhui Provincial Hospital
      2023   -   NCT06039436   China
   Boston Children's Hospital
      2023   Phase 3   NCT05600426   Canada;United States
   EBMT (European Group for Blood and Marrow Transplantation)
      2009   -   EUCTR2007-000902-55-DE   France;Germany;United Kingdom
   EBMT (European group for Blood and Marrow Transplantation)
      2008   Phase 2   EUCTR2007-000902-55-FR   France;Germany;United Kingdom
      2007   Phase 2   EUCTR2007-000902-55-GB   France;Germany;United Kingdom
   Memorial Sloan Kettering Cancer Center
      2018   Phase 1   NCT03531736   United States
   Michael Pulsipher
      2016   -   NCT02845596   United States
   National Heart, Lung, and Blood Institute (NHLBI)
      2005   Phase 2   NCT00260689   United States
   Navy General Hospital, Beijing
      2015   Phase 1/Phase 2   NCT02407470   China
   Novartis Pharmaceuticals
      2020   Phase 2   NCT04328727   China;Japan;Korea, Republic of;Taiwan
   St. Jude Children's Research Hospital
      2021   Phase 2   NCT04558736   United States
   The First Affiliated Hospital of Henan University of Science and Technology
      2023   Phase 0   ChiCTR2300077547   China
Rabbit antithymocyte globulin
   European Group for Blood and Marrow Transplantation
      2008   Phase 2   NCT00471848   France;Germany;Italy;Saudi Arabia;Switzerland;United Kingdom
Rabbit ATG
   Jinan Military General Hospital
      2017   Phase 4   NCT02838992   China
   King Faisal Specialist Hospital & Research Center
      2008   Phase 2   NCT01530555   -
   Masonic Cancer Center, University of Minnesota
      2024   Phase 2   NCT06412497   United States
   Northside Hospital, Inc.
      2016   Phase 2   NCT02828592   United States
   Novartis Pharmaceuticals
      2015   Phase 2   NCT02404025   Japan
Rabbit ATG, cyclosporine, levamisole
   Yizhou Zheng
      2014   Phase 2   NCT02203396   China
Rabbit human T lymphocyte immunoglobulin
   King's College Hospital NHS Foundation Trust
      2008   Phase 2   EUCTR2007-001657-26-GB   United Kingdom
Radiation therapy
   Case Comprehensive Cancer Center
      1998   Phase 2   NCT00003336   United States
   Memorial Sloan Kettering Cancer Center
      1995   Phase 2   NCT00002718   United States
Rapamune
   Karolinska Institutet
      2007   -   EUCTR2006-006577-25-SE   Finland;Sweden
   Peking Union Medical College Hospital
      2025   Phase 2   NCT06802055   China
Rapamycin
   Karolinska Institutet
      2007   -   EUCTR2006-006577-25-SE   Finland;Sweden
Ratg
   Ishiyama Ken
      2019   Phase 2   JPRN-jRCTs071190032   -
   The First Affiliated Hospital of Henan University of Science and Technology
      2023   Phase 0   ChiCTR2300077547   China
RD13-02
   Institute of Hematology & Blood Diseases Hospital, China
      2024   Phase 1   NCT06622694   China
Reduced dose OF cyclophosphamide combined with standard immunosuppressive therapy
   Institute of Hematology & Blood Diseases Hospital, China
      2024   Phase 2   NCT06695741   China
Reduced-dose conditioning regimen containing TBI IN hematopoietic stem cell transplantation treating elderly patients with aplastic anemia
   Institute of Hematology & Blood Diseases Hospital, China
      2025   Phase 2   NCT06769568   -
REGN7257
   Regeneron Pharmaceuticals
      2021   Phase 1/Phase 2   NCT04409080   France;Korea, Republic of;United Kingdom;United States
   Regeneron Pharmaceuticals, Inc.
      2020   Phase 1;Phase 2   EUCTR2020-002031-29-GB   France;Korea, Republic of;United Kingdom;United States
      2020   Phase 1;Phase 2   EUCTR2020-002031-29-FR   France;Korea, Republic of;United Kingdom;United States
Revolade
   European Society for Blood and Marrow Transplantation
      2016   Phase 3   EUCTR2014-000363-40-NL   Netherlands;Spain
      2015   -   EUCTR2014-000363-40-ES   Spain
   Melbourne Health
      2024   Phase 1/Phase 2   NCT06607367   Australia
   Novartis Farmacéutica, S.A
      2017   Phase 2   EUCTR2016-002814-29-ES   Brazil;Canada;France;Hong Kong;Hungary;India;Italy;Korea, Republic of;Mexico;Netherlands;Qatar;Spain;Turkey
   Novartis Pharma AG
      2019   Phase 2   EUCTR2015-003166-91-GB   Hong Kong;Netherlands;Portugal;Russian Federation;Thailand;United Kingdom;United States
      2018   Phase 2   EUCTR2015-003166-91-NL   Hong Kong;Netherlands;Portugal;Russian Federation;Thailand;United Kingdom;United States
      2017   Phase 2   EUCTR2016-002814-29-NL   Brazil;Hong Kong;Hungary;India;Italy;Korea, Republic of;Mexico;Netherlands;Spain;Thailand;Turkey
      2017   Phase 2   EUCTR2016-002814-29-HU   Brazil;France;Hong Kong;Hungary;India;Italy;Korea, Republic of;Mexico;Netherlands;Spain;Turkey
      2017   Phase 2   EUCTR2015-003166-91-PT   Hong Kong;Netherlands;Portugal;Russian Federation;Thailand;United Kingdom;United States
Revolade - 25 MG - compressa rivestita CON film - USO orale - blister(PA/ALU/PVC/ALU) 28 compresse
   NOVARTIS PHARMA AG
      2019   Phase 2   EUCTR2016-002814-29-IT   Brazil;Hong Kong;Hungary;India;Italy;Korea, Democratic People's Republic of;Mexico;Netherlands;Spain;Thailand;Turkey
Revolade - 50 MG - compressa rivestita CON film - USO orale - blister(PA/ALU/PVC/ALU
   NOVARTIS PHARMA AG
      2019   Phase 2   EUCTR2016-002814-29-IT   Brazil;Hong Kong;Hungary;India;Italy;Korea, Democratic People's Republic of;Mexico;Netherlands;Spain;Thailand;Turkey
Revolade 75 MG
   Universitätsklinikum Ulm
      2015   Phase 2;Phase 3   EUCTR2014-000174-19-DE   France;Germany;Switzerland
   Universitätsklinikum Ulm (Clinique universitaire dÚlm)
      2021   Phase 2;Phase 3   EUCTR2014-000174-19-FR   France;Germany;Italy;Netherlands;Switzerland;United Kingdom
Rhtpo
   Henan Cancer Hospital
      2022   -   ChiCTR2200056625   China
   Institute of Hematology, People's Hospital, Peking University
      2019   -   ChiCTR1800019669   China
   Peking Union Medical College Hospital
      2024   Phase 4   NCT06525948   China
   Suzhou Hongci Blood Disease Hospital
      2024   Phase 4   ChiCTR2400091592   China
   Tianjin Medical University General Hospital
      2016   Phase 2   NCT02857530   China
Rhtpo combined with herombopag + CSA
   Peking Union Medical College Hospital
      2023   Phase 4   NCT06004791   China
Rimiducid
   Bellicum Pharmaceuticals, Inc.
      2017   Phase 2   EUCTR2014-000584-41-ES   Italy;Spain;United Kingdom
      -   Phase 2   EUCTR2014-000584-41-GB   Italy;Spain;United Kingdom
Rituxan
   Memorial Sloan Kettering Cancer Center
      2018   Phase 1   NCT03531736   United States
Rituximab
   Institute of Hematology & Blood Diseases Hospital, China
      2023   Phase 2   NCT06254560   China
   M.D. Anderson Cancer Center
      2017   Phase 1   NCT02960646   United States
   Masonic Cancer Center, University of Minnesota
      2024   Phase 2   NCT06412497   United States
      2018   Phase 2   NCT03579875   United States
   National Heart, Lung, and Blood Institute (NHLBI)
      2005   Phase 2   NCT00229619   United States
Rivogenlecleucel
   Bellicum Pharmaceuticals, Inc.
      -   Phase 2   EUCTR2014-000584-41-GB   Italy;Spain;United Kingdom
Rivogenleucleucel
   Bellicum Pharmaceuticals, Inc.
      2017   Phase 2   EUCTR2014-000584-41-ES   Italy;Spain;United Kingdom
RNA analysis
   City of Hope Medical Center
      2010   -   NCT01199562   United States
Romiplostim
   Amgen
      2023   Phase 2   NCT05323617   -
   Anjali Sharathkumar
      2020   Early Phase 1   NCT04478227   United States
   Kyowa Kirin Co., Ltd
      2019   Phase 2-3   JPRN-jRCT2080224878   Asia except Japan;Japan
      2019   Phase 2-3   JPRN-jRCT2080224673   Asia except Japan;Japan
   Kyowa Kirin Co., Ltd.
      2019   Phase 2/Phase 3   NCT04095936   Japan
      2019   Phase 2/Phase 3   NCT03957694   Japan
      2016   Phase 2/Phase 3   NCT02773290   Japan;Korea, Republic of
      2016   Phase 2-3   JPRN-jRCT2080223188   Asia except Japan;Japan
   Peking Union Medical College Hospital
      2024   Phase 4   NCT06535685   China
      2024   Phase 4   NCT06516484   China
      2023   Phase 4   NCT06009497   China
   Shimonaga Contact Masahiro
      2023   Phase 2   JPRN-jRCT2031230178   -
   Tianjin Medical University General Hospital
      2024   Phase 4   ChiCTR2400085301   China
Ruxolitinib
   Fred Hutchinson Cancer Center
      2025   Phase 2   NCT06752694   United States
   Melbourne Health
      2024   Phase 1/Phase 2   NCT06607367   Australia
   National Heart, Lung, and Blood Institute (NHLBI)
      2024   Phase 1/Phase 2   NCT05998408   United States
   The Second Affiliated Hospital of Dalian Medical University
      2021   -   ChiCTR2100051874   China
Ruxolitinib 5 MG BID oral tablet
   Institute of Hematology & Blood Diseases Hospital
      2023   Phase 2   NCT05914714   -
RVG 101614
   VU University Medical Center
      2015   Phase 4   EUCTR2014-001546-25-NL   Netherlands
RVG 105155
   VU University Medical Center
      2015   Phase 4   EUCTR2014-001546-25-NL   Netherlands
Sandimmun neoral
   Karolinska Institutet
      2007   -   EUCTR2006-006577-25-SE   Finland;Sweden
Sandimmun neoral - 100 MG capsule molli 30 capsule
   NOVARTIS PHARMA AG
      2019   Phase 2   EUCTR2016-002814-29-IT   Brazil;Hong Kong;Hungary;India;Italy;Korea, Democratic People's Republic of;Mexico;Netherlands;Spain;Thailand;Turkey
Sandimmun neoral - 25 MG capsule molli 50 capsule
   NOVARTIS PHARMA AG
      2019   Phase 2   EUCTR2016-002814-29-IT   Brazil;Hong Kong;Hungary;India;Italy;Korea, Democratic People's Republic of;Mexico;Netherlands;Spain;Thailand;Turkey
Sandimmun neoral - 50 MG capsule molli 50 capsule
   NOVARTIS PHARMA AG
      2019   Phase 2   EUCTR2016-002814-29-IT   Brazil;Hong Kong;Hungary;India;Italy;Korea, Democratic People's Republic of;Mexico;Netherlands;Spain;Thailand;Turkey
Sargramostim
   Roswell Park Cancer Institute
      2002   Phase 2   NCT00053989   United States
      2002   -   NCT00053157   United States
SB497115
   Universitätsklinikum Ulm
      2015   Phase 2;Phase 3   EUCTR2014-000174-19-DE   France;Germany;Switzerland
   Universitätsklinikum Ulm (Clinique universitaire dÚlm)
      2021   Phase 2;Phase 3   EUCTR2014-000174-19-FR   France;Germany;Italy;Netherlands;Switzerland;United Kingdom
Sirolimus
   Fred Hutchinson Cancer Center
      2025   Phase 2   NCT06752694   United States
   Fred Hutchinson Cancer Research Center
      2006   Phase 2   NCT00358657   United States
   Karolinska Institutet
      2007   -   EUCTR2006-006577-25-SE   Finland;Sweden
   National Heart, Lung, and Blood Institute (NHLBI)
      2016   Phase 2   NCT02979873   United States
   Office of Rare Diseases (ORD)
      2006   Phase 1/Phase 2   NCT00319878   United States
   Peking Union Medical College Hospital
      2025   Phase 2   NCT06802055   China
   Peking University People's Hospital
      2024   Phase 1/Phase 2   NCT06279494   -
   Roswell Park Cancer Institute
      2017   Phase 1/Phase 2   NCT03192397   United States
Sodium chloride
   EBMT (European group for Blood and Marrow Transplantation)
      2008   Phase 2   EUCTR2007-000902-55-FR   France;Germany;United Kingdom
      2007   Phase 2   EUCTR2007-000902-55-GB   France;Germany;United Kingdom
Standard IST combined with romiplostim N01
   Institute of Hematology & Blood Diseases Hospital, China
      2024   Phase 2   NCT06613880   China
Standard therapy OF septic shock
   National Research Center for Hematology, Russia
      2012   Phase 1/Phase 2   NCT01849237   Russian Federation
Standard vitamin D3 supplementation
   Phoenix Children's Hospital
      2017   Phase 4   NCT03176849   United States
Stanozolol
   The First Affiliated Hospital of Zhengzhou University
      2016   -   ChiCTR-IOR-16008738   China
Stem cell infusion
   Baylor College of Medicine
      2002   Phase 2   NCT00578903   United States
   The Second Affiliated Hospital of Xi'an Jiaotong University (Xibei Hospital)
      2021   Phase 0   ChiCTR2100047288   China
Stem cell transplant
   Masonic Cancer Center, University of Minnesota
      2015   -   NCT02162420   United States
Stem cell transplantation
   Jiangsu Province Hospital
      2020   Phase 4   ChiCTR2100045895   China
   Masonic Cancer Center, University of Minnesota
      2007   Phase 2/Phase 3   NCT00455312   United States
   Sidney Kimmel Cancer Center at Thomas Jefferson University
      2010   Phase 2   NCT01350245   United States
   Zhejiang Provincial Hospital of Traditional Chinese Medicine
      2021   -   ChiCTR2100050948   China
Sulfameth
   José Miguel Cisneros Herreros
      2012   Phase 3   EUCTR2011-005152-34-ES   Spain
T CELL-depleted donor lymphocyte infusion
   Sidney Kimmel Cancer Center at Thomas Jefferson University
      2015   Phase 2   NCT02566304   United States
Tacrolimus
   Boston Children's Hospital
      2012   Phase 2   NCT01659606   Norway;Sweden;United States
   Fred Hutchinson Cancer Research Center
      2006   Phase 2   NCT00358657   United States
   Karolinska Institutet
      2007   -   EUCTR2006-006577-25-SE   Finland;Sweden
   M.D. Anderson Cancer Center
      2017   Phase 1   NCT02960646   United States
   Masonic Cancer Center, University of Minnesota
      2024   Phase 2   NCT06412497   United States
   Medical College of Wisconsin
      2017   Phase 2   NCT02918292   United States
   Peking Union Medical College Hospital
      2020   Phase 2   NCT04403321   China
   Roswell Park Cancer Institute
      2012   Phase 2   NCT01529827   United States
      2002   Phase 2   NCT00053989   United States
   Sidney Kimmel Cancer Center at Thomas Jefferson University
      2015   Phase 2   NCT02566304   United States
      2012   Phase 2   NCT01760655   United States
      2011   Phase 2   NCT01384513   United States
      2010   Phase 2   NCT01350245   United States
   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
      2016   Phase 2   NCT02833805   United States
      2014   Phase 2   NCT02224872   United States
   The First Affiliated Hospital of Henan University of Science and Technology
      2023   Phase 0   ChiCTR2300077547   China
   Thomas Jefferson University
      2021   Phase 2   NCT05031897   United States
   University of California, San Francisco
      2005   -   NCT00295997   United States
TBI
   Baylor College of Medicine
      2002   Phase 2   NCT00578903   United States
   Boston Children's Hospital
      2023   Phase 3   NCT05600426   Canada;United States
   Kanto Study Group for Cell Therapy
      2011   Phase 2   JPRN-UMIN000006071   Japan
   M.D. Anderson Cancer Center
      2006   Phase 1/Phase 2   NCT00474747   United States
   Masonic Cancer Center, University of Minnesota
      2018   Phase 2   NCT03579875   United States
   Medical College of Wisconsin
      2017   Phase 2   NCT02918292   United States
   Michael Pulsipher
      2016   -   NCT02845596   United States
   National Institute of Blood and Marrow Transplant (NIBMT), Pakistan
      2018   Phase 2   NCT03955601   Pakistan
   Shanghai Children's Medical Center affiliated to Shanghai Jiao Tong University School of Medicine
      2017   Phase 0   ChiCTR1900023509   China
   Sidney Kimmel Cancer Center at Thomas Jefferson University
      2011   Phase 2   NCT01384513   United States
      2010   Phase 2   NCT01350245   United States
   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
      2014   Phase 2   NCT02224872   United States
Testosterone undecanoate
   Jinhua people's Hospital
      2015   Phase 2-3   ChiCTR1900028153   -
Therapeutic allogeneic lymphocytes
   Roswell Park Cancer Institute
      2002   Phase 2   NCT00053989   United States
   Sidney Kimmel Cancer Center at Thomas Jefferson University
      2012   Phase 2   NCT01760655   United States
   University of California, San Francisco
      2005   -   NCT00295997   United States
Thiotepa
   King's College Hospital NHS Foundation Trust
      2008   Phase 2   EUCTR2007-001657-26-GB   United Kingdom
   Memorial Sloan Kettering Cancer Center
      1995   Phase 2   NCT00002718   United States
   Roswell Park Cancer Institute
      1998   Phase 2/Phase 3   NCT00003816   United States
Thymoglobulin
   EBMT (European Group for Blood and Marrow Transplantation)
      2009   -   EUCTR2007-000902-55-DE   France;Germany;United Kingdom
   EBMT (European group for Blood and Marrow Transplantation)
      2008   Phase 2   EUCTR2007-000902-55-FR   France;Germany;United Kingdom
      2007   Phase 2   EUCTR2007-000902-55-GB   France;Germany;United Kingdom
   Kanto Study Group for Cell Therapy
      2011   Phase 2   JPRN-UMIN000006071   Japan
   King's College Hospital NHS Foundation Trust
      2008   Phase 2   EUCTR2007-001657-26-GB   United Kingdom
   M.D. Anderson Cancer Center
      2005   Phase 2   NCT00806598   United States
   Nagoya University
      2012   Phase 3   NCT01844635   Japan
      2012   -   JPRN-UMIN000011134   Japan,Asia(except Japan)
   Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
      2016   Phase 4   NCT02745717   China
   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
      2016   Phase 2   NCT02833805   United States
      2014   Phase 2   NCT02224872   United States
   The Korean Society of Pediatric Hematology Oncology
      2006   Phase 2   NCT00737685   Korea, Republic of
Thymoglobuline
   EBMT (European Group for Blood and Marrow Transplantation)
      2009   -   EUCTR2007-000902-55-DE   France;Germany;United Kingdom
   EBMT (European group for Blood and Marrow Transplantation)
      2008   Phase 2   EUCTR2007-000902-55-FR   France;Germany;United Kingdom
      2007   Phase 2   EUCTR2007-000902-55-GB   France;Germany;United Kingdom
   King Faisal Specialist Hospital & Research Center
      2008   Phase 2   NCT01530555   -
Thymoglobuline 5 MG/ML, poudre pour solution pour perfusion
   Amgen, Inc.
      2023   Phase 2   EUCTR2022-001257-22-FR   Brazil;France;United Kingdom;United States
Total body irradiation
   Asan Medical Center
      2012   Phase 2   NCT01759732   Korea, Republic of
   Baylor College of Medicine
      2002   Phase 2   NCT00578903   United States
   Boston Children's Hospital
      2023   Phase 3   NCT05600426   Canada;United States
   M.D. Anderson Cancer Center
      2006   Phase 1/Phase 2   NCT00474747   United States
   Masonic Cancer Center, University of Minnesota
      2024   Phase 2   NCT06412497   United States
      2018   Phase 2   NCT03579875   United States
      2015   -   NCT02162420   United States
      2007   Phase 2/Phase 3   NCT00455312   United States
   Medical College of Wisconsin
      2017   Phase 2   NCT02918292   United States
   Memorial Sloan Kettering Cancer Center
      2018   Phase 1   NCT03531736   United States
   Michael Pulsipher
      2016   -   NCT02845596   United States
   Northside Hospital, Inc.
      2016   Phase 2   NCT02828592   United States
   Sidney Kimmel Cancer Center at Thomas Jefferson University
      2011   Phase 2   NCT01384513   United States
      2010   Phase 2   NCT01350245   United States
   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
      2016   Phase 2   NCT02833805   United States
Total body irradiation 1200 CGY
   University of Rochester
      2015   Phase 1   NCT03016806   United States
Total body irradiation 200 CGY
   University of Rochester
      2015   Phase 1   NCT03016806   United States
Total-body irradiation
   Fred Hutchinson Cancer Center
      2025   Phase 2   NCT06752694   United States
   Fred Hutchinson Cancer Research Center
      2006   Phase 2   NCT00358657   United States
      2006   Phase 1   NCT00354419   United States
   M.D. Anderson Cancer Center
      2019   Phase 1/Phase 2   NCT03622788   United States
      2017   Phase 1   NCT02960646   United States
   Roswell Park Cancer Institute
      2017   Phase 2   NCT03333486   United States
      2017   Phase 1/Phase 2   NCT03192397   United States
      2012   Phase 2   NCT01529827   United States
      2009   -   NCT00856388   United States
      1998   Phase 2/Phase 3   NCT00003816   United States
   Sidney Kimmel Cancer Center at Thomas Jefferson University
      2015   Phase 2   NCT02566304   United States
      2012   Phase 2   NCT01760655   United States
   Thomas Jefferson University
      2021   Phase 2   NCT05031897   United States
Trappa ethanolamine tablets
   Jiangsu HengRui Medicine Co., Ltd.
      2023   Phase 2   NCT05797623   China
Trimethoprim sulfate
   José Miguel Cisneros Herreros
      2012   Phase 3   EUCTR2011-005152-34-ES   Spain
Umbilical cord blood
   National Heart, Lung, and Blood Institute (NHLBI)
      2008   Phase 2   NCT00604201   United States
   Tianjin Medical University General Hospital
      2023   -   ChiCTR2300072983   China
   West Virginia University
      2009   -   NCT01768845   United States
Umbilical cord blood after myeloablative conditioning
   Tufts Medical Center
      2005   Phase 2   NCT00676806   United States
Umbilical cord blood after reduced-intensity conditioning
   Tufts Medical Center
      2005   Phase 2   NCT00676806   United States
Umbilical cord blood transplantation
   Case Comprehensive Cancer Center
      2002   Phase 1   NCT00054236   United States
      1998   Phase 2   NCT00003336   United States
   Fred Hutchinson Cancer Research Center
      2006   Phase 1   NCT00354419   United States
   New York Blood Center
      1993   Early Phase 1   NCT00212407   United States
   Roswell Park Cancer Institute
      2002   Phase 2   NCT00053989   United States
Unrelated donor bone marrow transplant
   Medical College of Wisconsin
      2025   Phase 2   NCT06517641   United States
Valganciclovir
   City of Hope Medical Center
      2010   -   NCT01199562   United States
Voriconazole
   Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC
      2013   -   ChiCTR-PRC-13003130   China